Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer

Journal of Clinical Oncology

Volumn 18, Issue 17, 2000, Pages 3084-3092

  Neijt, Jan P ^a   Engelholm, Svend A ^a   Tuxen, Malgorzata K ^a   Sørensen, Peter G ^a   Hansen, Mogens ^a   Sessa, Cristiana ^a   De Swart, Cees A M ^a   Hirsch, Fred R ^a   Lund, Birthe ^a   Van Houwelingen, Hans C ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; CARBOPLATIN; CIMETIDINE; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL; RANITIDINE;

ADULT; ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; GRANULOCYTOPENIA; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; NEUROTOXICITY; OUTPATIENT; OVARY CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 0033850178     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.17.3084     Document Type: Article

References (19)

1. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
2. New therapy for ovarian cancer
3. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion
4. Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: Unexpected incidence of neurotoxicity
5. Carboplatin versus cisplatin in solid tumors: An analysis of the literature
6. Carboplatin versus cisplatin
7. Reporting results of cancer treatment
8. Use of tumour markers in monitoring the course of ovarian cancer
9. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
10. Prediction of creatinine clearance from serum creatinine
11. 2 over 3 hours) with cisplatin or carboplatin in previously untreated ovarian cancer: An interim analysis
12. Nonparametric estimation from incomplete observations
13. Regression models in life-tables
14. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer: London Gynaecological Oncology Group
15. Dose-effect study of carboplatin in ovarian cancer: A Danish Ovarian Cancer Group study
16. ICON2: Randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer
17. A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel
18. Higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet counts
19. Advanced epithelial ovarian cancer: 1998 consensus statements